AAPS Workshop Report: Strategies to Address Therapeutic Protein–Drug Interactions during Clinical Development-Reference-Cited by-同舟云学术

AAPS Workshop Report: Strategies to Address Therapeutic Protein–Drug Interactions during Clinical Development

Published:2011-06-01 Issue:3 Volume:13 Page:405-416
ISSN:1550-7416
Container-title:The AAPS Journal
language:en
Short-container-title:AAPS J

Author:

Girish Sandhya,Martin Steven W,Peterson Mark C,Zhang Lei K.,Zhao Hong,Balthasar Joseph,Evers Raymond,Zhou Honghui,Zhu Min,Klunk Lewis,Han Chao,Berglund Eva Gil,Huang Shiew-Mei,Joshi Amita

Publisher

Springer Science and Business Media LLC

Subject

Pharmaceutical Science

Link

https://link.springer.com/content/pdf/10.1208/s12248-011-9285-6.pdf

Reference42 articles.

1. Lee JI, Zhang L, Men AY, Kenna LA, Huang SM. CYP-medicated therapeutic protein–drug interactions clinical findings, proposed mechanisms and regulatory implications. Clin Pharmacokinet. 2010;49(5):295–310.

2. Huang S-M, Zhao H, Lee JI, Reynolds K, Zhang L, Temple R, et al. Therapeutic protein–drug interactions and implications for drug development. Clin Pharmacol Ther. 2010;87:497–503.

3. Seitz K, Zhou H. Pharmacokinetic drug–drug interaction potentials for therapeutic monoclonal antibodies: reality check. J Clin Pharmacol. 2007;47:1104–18.

4. Zhou H, Davis HM. Risk-based strategy for the assessment of pharmacokinetic drug–drug interactions for therapeutic monoclonal antibodies. Drug Discov Today. 2009;14(17–18):891–8.

5. Mahmood I, Green MD. Drug interaction studies of therapeutic proteins or monoclonal antibodies. J Clin Pharmacol. 2007;47:1540–54.

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nonclinical drug development;Atkinson's Principles of Clinical Pharmacology;2022

2. Evaluating Potential Disease‐Mediated Protein‐Drug Interactions in Patients With Moderate‐to‐Severe Plaque Psoriasis Receiving Subcutaneous Guselkumab;Clinical and Translational Science;2020-05-28

3. The interleukin-17 G-197A polymorphism is associated with cyclosporine metabolism and transplant rejection in liver transplant recipients;Pharmacogenomics;2019-04

4. Investigation of the Mechanism of Therapeutic Protein-Drug Interaction Between Methotrexate and Golimumab, an Anti-TNFα Monoclonal Antibody;The AAPS Journal;2018-04-17

5. Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study;Clinical Cancer Research;2018-01-22